Letter to FDA Opposing Approval of Liraglutide (Victoza) for Cardiovascular Risk Reduction

July, 18, 2017

View as PDF.

View June 20, 2017 testimony.

FDA response letter to Public Citizen on Victoza cardiovascular risk, July 27, 2017.

In a letter to the Food and Drug Administration (FDA), Public Citizen urged the FDA not to approve liraglutide (Victoza) for the additional indication of reducing cardiovascular risk in type 2 diabetes patients because the clinical trial to support such approval failed to show any benefit in the 2,500 U.S. subjects in the trial. The study only showed a significant benefit in non-U.S. subjects.

View Public Citizen’s previous work on liraglutide.